Format

Send to

Choose Destination
Life Sci. 2019 May 1;224:120-127. doi: 10.1016/j.lfs.2019.03.053. Epub 2019 Mar 22.

Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.

Author information

1
Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, Brescia, Italy.
2
Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden.
3
Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, Brescia, Italy. Electronic address: andrea.mastinu@unibs.it.

Abstract

The pharmacological research on the Cannabis sativa-derived compounds has never terminated. Among the phytocannabinoids without psychotropic effects, the prevalent one in Cannabis is cannabidiol (CBD). Although CBD was initially considered a type 2 cannabinoid receptor (CB2R) antagonist, it did not show a good cannabinoidergic activity. Furthermore, heterogeneous results were obtained in experimental animal models of anxiety disorders, psychotic stages and neurodegenerative diseases. Recently, CBD has been authorized by the FDA to treat some rare forms of epilepsy and many trials have begun for the treatment of autism spectrum disorders. This review aims to clarify the pharmacological activity of CBD and its multiple therapeutic applications. Furthermore, critical and conflicting results of the research on CBD are discussed with a focus on promising future prospects.

KEYWORDS:

Cannabidiol; Cannabis sativa; Epilepsy; Psychiatric disorders

PMID:
30910646
DOI:
10.1016/j.lfs.2019.03.053

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center